Every 10-Q that GOLDENWELL BIOTECH INC (GWLL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GWLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GWLL filings page.
Goldenwell Biotech, Inc. reported no revenue for the three- and six-month periods ended June 30, 2026 and remains a pre-revenue development-stage company. For the six months, it recorded a net loss of $54,482, an improvement from a $68,836 loss (as restated) in the prior-year period, driven primarily by modestly higher general and administrative expenses but some other income.
Total assets were $28,978, including cash of $11,143 and a prepaid OTCQB fee of $17,835. Total liabilities were $427,173, resulting in stockholders’ deficit of $(398,195) and working capital of $(398,195). The company has an outstanding related-party loan of $140,588 from its CEO and recognized $100,000 of unearned service revenue from a related-party contract.
Management disclosed an accumulated deficit of $1,710,598 and stated there is substantial doubt about the company’s ability to continue as a going concern. Operating cash outflows were $60,632 for the six months, partially offset by $45,000 of new related-party financing. Prior 2025 financial statements were restated for errors in revenue recognition, legal expense accruals and prepaid fee classification, and disclosure controls and procedures were concluded to be not effective.
Goldenwell Biotech, Inc. reported no revenue for the quarter ended March 31, 2026 and a net loss of $17,606, an improvement from a $38,536 loss a year earlier. Operating expenses were $31,335, partly offset by $15,829 of other income, including legal settlement and breakage income.
The company had cash of $13,414 and total assets of $18,754 against total liabilities of $380,073, resulting in stockholders’ deficit of $361,319. Management discloses substantial doubt about its ability to continue as a going concern, citing an accumulated deficit of $1,673,722 and dependence on raising additional capital.
Goldenwell estimates it needs about $5,000,000 to build manufacturing capacity and scale operations and plans to seek debt or equity financing, though no arrangements are in place. The company also restated prior 2025 quarterly figures to correct the timing of a $4,160 legal expense accrual.
Goldenwell Biotech, Inc. filed an amended quarterly report for the period ended September 30, 2025 to fully restate its financial statements after its auditor identified material GAAP errors. The restatement removed $25,000 of service revenue, added a $13,350 prepaid OTCQB fee asset, and adjusted legal fees, increasing Q3 2025 net loss from $7,985 to $27,895.
For the nine months ended September 30, 2025, the company reported no revenue and a net loss of $96,731, bringing its accumulated deficit to $1,456,377. At September 30, 2025, cash was $45,622, total assets were $233,760, total liabilities were $377,733, and stockholders’ equity was a deficit of $143,974. A related-party loan totaled $95,588, and management disclosed substantial doubt about the company’s ability to continue as a going concern.
Goldenwell Biotech, Inc. filed Amendment No. 1 to its quarterly report for the period ended June 30, 2025 to fully restate its financial statements and related disclosures. The restatement reverses previously recorded service revenue and reclassifies certain legal and OTC Markets fees to comply with US GAAP.
For the six months ended June 30, 2025, the Company generated no revenue and recorded a net loss of $68,836, bringing its accumulated deficit to $1,428,481. At June 30, 2025, Goldenwell reported cash of $76,507, total assets of $267,315, total liabilities of $383,393, and stockholders’ deficit of $116,079, and its auditors and management highlighted substantial doubt about its ability to continue as a going concern.
Goldenwell Biotech, Inc. filed an amended quarterly report to fully restate its financial statements for the quarter ended March 31, 2025 after determining earlier figures could no longer be relied upon. The restatement mainly records a previously unaccrued legal fee, increasing legal expense by $4,160 and raising the quarterly net loss to $38,536.
For the quarter, the company generated no revenue, incurred $36,436 in general and administrative costs and reported a basic and diluted loss per share of zero on 99,000,000 shares. Cash was $17,127 against current liabilities of $277,693, resulting in stockholders’ deficit of $85,778 and an accumulated deficit of $1,398,181.
Management discloses substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses, lack of revenue and reliance on capital raising. The company has a $95,599 related-party long-term loan and estimates it will need about $5,000,000 to build manufacturing capacity and scale its nutraceutical and supplement business.
Goldenwell Biotech, Inc. reports third-quarter 2025 results that highlight its early-stage status and financial strain. For the quarter ended September 30, 2025, the company generated $25,000 in service revenue and no product sales, leading to a net loss of $7,985. For the first nine months of 2025, revenue from services was $62,500 and the net loss was $47,581, an improvement from a $103,962 loss a year earlier.
As of September 30, 2025, Goldenwell held $45,622 in cash, total assets of $220,410 and total liabilities of $315,233, resulting in negative stockholders’ equity of $94,823. The company has an accumulated deficit of $1,407,226 and a $95,588 related-party loan from its chief executive officer. Management and the auditors state that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and the business will require significant new financing to pursue its plan to scale nutraceutical and dietary supplement operations.
Goldenwell Biotech, Inc. reports minimal early-stage operations and continuing losses for the quarter and six months ended June 30, 2025. The company generated mainly service revenue of $37,500 in the six-month period, with only negligible product sales, and recorded a net loss of $39,596, bringing its accumulated deficit to $1,399,241 since inception.
At June 30, 2025, Goldenwell had total assets of $251,295, including cash of $76,507 and inventory of $174,788, against total liabilities of $350,633, resulting in negative stockholders’ equity. Management discloses a working capital deficit and an outstanding related-party loan of $95,588, and states that substantial doubt exists about the company’s ability to continue as a going concern.
The company plans to expand its nutraceutical and dietary supplements business but estimates it will need about $5,000,000 to build manufacturing facilities and scale operations. Management indicates that additional capital will likely need to come from debt or equity offerings, with no assurance such financing can be obtained.